PPP2R2A and cancer: Thus, despite the complexity of PPP2R2A deficiency in the regulation of oncogenic signaling and cancer therapy in the different types of cancer, its impact on the increased sensitivity to CHK1 inhibition in NSCLC and HGSOC appears to be similar.